When evaluating receptivity of a patient and tumor to immune checkpoint blockade, why are total mutational burden and genomic stability as important as expression of the IC receptor?

When evaluating receptivity of a patient and tumor to immune checkpoint blockade, why are total mutational burden and genomic stability as important as expression of the IC receptor?

When evaluating the receptivity of a patient and tumor to immune checkpoint blockade, why are total mutational burden and genomic stability — chromosome deletions and additions — as important as expression of the IC receptor?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Prof. Jean-Yves Blay, MD, PhD

Prof. Jean-Yves Blay, MD, PhD

Professor of Medicine
Université Claude Bernard
Lyon, France
Scientific Director
Canceropole Lyon Rhône Alpes